Robert Peirce & Associates, P.C. Attorneys Appointed to Leadership Roles in National Depo-Provera Litigation

Robert Peirce & Associates, P.C. is proud to announce that two of our firm’s attorneys have been appointed to pivotal leadership roles in the ongoing national litigation involving Depo-Provera, a contraceptive injection linked to serious health risks, including brain tumors.

Partner D. Aaron Rihn Appointed Pennsylvania Liaison

In a recent Pretrial Order for Leadership Appointments, D. Aaron Rihn was named the Pennsylvania Liaison in the Depo-Provera litigation. As part of this important appointment, Mr. Rihn is tasked with responsibilities that include:

• Keeping co-counsel and the Court apprised of motions, orders, and significant developments in related Pennsylvania state court actions.
• Facilitating communication between state and federal courts by sharing pertinent filings and orders from both jurisdictions.
• Assisting in coordinated court proceedings between the MDL and state court systems.

Aaron’s appointment reflects the trust placed in him by the Court and his colleagues across the country. As a seasoned litigator with decades of experience in complex cases, Aaron has long been recognized for his strategic insight, collaborative leadership, and tireless advocacy on behalf of injured plaintiffs.

Associate Sara Watkins Named to Class Action Committee

In addition to Mr. Rihn’s appointment, Sara Watkins has been named to the Court’s Class Action Committee. This committee is tasked with overseeing medical monitoring class action proceedings and advising the Court on key issues that need to be addressed or briefed.

Sara brings extensive experience to this role. She has pursued pharmaceutical and medical device litigation across the country and is leading the firm’s ongoing efforts in the Depo-Provera litigation. Her commitment to standing up for victims harmed by dangerous drugs is evident in every case she handles.

“I am dedicated to fight for women who now fall victim to the manufacturers of Depo-Provera,” said Watkins. “The manufacturers should have warned patients of the risks of this contraceptive. These women were told their contraceptives were safe, only to now suffer from brain tumors with serious symptoms that affect their everyday lives.”

Sara’s leadership position underscores her reputation as a fierce advocate for consumer safety and justice—especially for women harmed by negligent pharmaceutical companies.

About the Depo-Provera Litigation

Depo-Provera and Depo-SubQ Provera 104 are brand-name contraceptive injections containing medroxyprogesterone acetate, a synthetic form of the hormone progesterone. Mounting evidence suggests that prolonged use of these drugs may be linked to an increased risk of developing intracranial meningiomas—tumors that grow on the membranes surrounding the brain and spinal cord.

Women who used these contraceptives and were later diagnosed with intracranial meningioma may have grounds to pursue legal action.

At Robert Peirce & Associates, P.C., we are currently investigating claims nationwide. You may qualify if:

• You used brand-name Depo-Provera/Depo-SubQ Provera 104 or their authorized generics
• You were diagnosed with an intracranial meningioma
• You used the drug for at least one year (four injections)
• Your usage occurred at least six months before diagnosis

Committed to Advocacy and Accountability

Our attorneys’ appointments to leadership roles in the Depo-Provera litigation are a testament to their experience, dedication, and the respect they have earned within the legal community. As always, we remain committed to fighting for individuals harmed by corporate negligence and unsafe pharmaceutical products.

If you or a loved one used Depo-Provera and were later diagnosed with a brain tumor, we encourage you to reach out. Our team is here to help you understand your rights and explore your legal options.